MeiraGTx
Company

Last deal

$50M

Amount

Post-IPO Equity

Stage

12.08.2024

Date

5

all rounds

$162.7M

Total amount

General

About Company
MeiraGTx is a gene therapy company developing and commercializing innovative treatments for patients with acquired and inherited disorders.

Industry

Sector :

Subsector :

Also Known As

Kadmon Gene Therapy

founded date

20.03.2015

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

With a focus on neurodegenerative diseases like Alzheimer's and Parkinson's, MeiraGTx is pioneering the use of gene therapy to transform the lives of patients. They also develop treatments for ocular diseases and side effects of radiation treatment. Their gene regulation technologies have the potential to revolutionize gene therapy and biologic therapeutics.
Contacts

Phone number

Social url